



(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
MSB-7257-DIV

Total Pages in this Submissio

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:											
Interleukin-2 Mutein Expressed from Mammalian Cells											
and in	and invented by:										
Sh	Sham-Yuen Chan, et al.										
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:											
phis phis		nuat	ion 🛚	Divisional		Continuation	-in-part (CIP)	of prior application No.:	09/310,026		
	Which is a: Continuation Divisional Continuation-in-part (CIP) of prior application No.:										
Enclo	Enclosed are:										
Application Elements											
1. 🗵 Filing fee as calculated and transmitted as described below											
2.	X	Spe	cification	having		12	_ pages and ir	ncluding the following:			
	a.	X	Descriptive Title of the Invention								
	b.	\boxtimes	Cross References to Related Applications (if applicable)								
	C.		Statement Regarding Federally-sponsored Research/Development (if applicable)								
	d.		Reference to Microfiche Appendix (if applicable)								
	e.	\boxtimes	Background of the Invention								
	f.	\boxtimes	Brief Summary of the Invention								
	g.	X	Brief Description of the Drawings (if drawings filed)								
	h.		Detailed Description								
	i.	X	Claim(s)) as Classified	Belo)W					
	j.	X	Abstract	t of the Disclo	sure						

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. MSB-7257-DIV

Total Pages in this Submission _2125

Drawing(s) (when necessary as prescribed by 35 USC 113) M a. 🔲 Formal Number of Sheets b. 🛛 Informal Number of Sheets X Oath or Declaration Newly executed (original or copy) Unexecuted a. 🔲 Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only) b. 🛛 With Power of Attorney Without Power of Attorney c. 🛛 **DELETION OF INVENTOR(S)** d. 🔲 Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b). Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. Computer Program in Microfiche (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included) Paper Copy a. 🛛 Computer Readable Copy (identical to computer copy) Statement Verifying Identical Paper and Computer Readable Copy **Accompanying Application Parts** Assignment Papers (cover sheet & document(s)) 37 CFR 3.73(B) Statement (when there is an assignee) 9. English Translation Document (if applicable) 10. Information Disclosure Statement/PTO-1449 Copies of IDS Citations 11. **Preliminary Amendment** 12. Acknowledgment postcard Certificate of Mailing 14. Express Mail (Specify Label No.): First Class

Application Elements (Continued)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. MSB-7257-DIV

Total Pages in this Submission

		Accompanying Application Parts (Continued)						
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)						
16. 🛚		Additional Enclosures (please identify below):						
		Statement - Sequence Listing:						
		The information contained on the Computer Readable Copy is identical to the information in the paper copy Statement						
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)						
17.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.						
		Warning						
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i).						

country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. MSB-7257-DIV

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed #Extra Rate Fee Total Claims 7 - 20 = \$0.00 \$18.00 0 X Indep. Claims 3 - 3 = \$80.00 \$0.00 0 X Multiple Dependent Claims (check if applicable) \$0.00 BASIC FEE \$710.00 OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$710.00 A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 03-4000 as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of the control of the charge the amount of the charge the amount of the charge th \$710.00 as filing fee. ☑ Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Melins a Shaw Signature December 14,2001 Dated: Melissa A. Shaw, Reg. No. 38,301 **Attorney for Applicants Bayer Corporation** 800 Dwight Way, P. O. Box 1986

CC:

Berkeley, California 94701



Pharmaceutical Division Bayer Corporation 800 Dwight Way P.O. Box 1986 Berkeley, CA 94701-1986

L. LeGrande-APCI

FIRST CLASS

2023 SSIStant Commissioner For Patents ox: Patent Application Dashing tou. D.

